inhibition of the tyrosine–tyrosinase reaction by phenylalanine or related abnormal aromatic metabolites which accumulate in the blood of patients with phenylketonuria. You have full access to ...

If such drugs can be developed, they might be less likely to be oncogenic for the reasons discussed, in contrast to ATP-competitive inhibitors. The feasibility of this approach has been shown by ...

All NSAIDs variably inhibit COX-1 and COX-2 and the mechanisms of inhibition fall into three broad categories, although there are exceptions. For example, nimesulide is a weak competitive ...